Table 2.
Characteristics of the ACOS patients treated with budesonide/formoterol
| Age, years | 67.7±10.8 |
| Body mass index, kg/m2 | 22.8±3.7 |
| Smoking, pack years | 52.8±36.2 |
| Male sex, % | 70.0 |
| CAT score | 13.4±8.0 |
| Post-bronchodilator | |
| VC, %predicted | 89.4±13.1 |
| FEV1, L | 1.45±0.58 |
| FEV1 %predicted | 57.2±17.5 |
| FEV1/FVC | 51.9±10.7 |
| RV, L | 2.59±1.21 |
| TLC, L | 5.74±2.48 |
| RV/TLC, %predicted | 125.4±17.6 |
| DLCO/VA, %predicted | 78.3±26.6 |
Note: Data are expressed as mean ± standard deviation.
Abbreviations: ACOS, asthma–chronic obstructive pulmonary disease overlap syndrome; CAT, chronic obstructive pulmonary disease assessment test; DLCO/VA, diffusing capacity for carbon monoxide per liter of lung volume; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity; VC, vital capacity.